New progress in immunotherapy of solid tumors targeting B7-H3
10.12354/j.issn.1000-8179.2024.20241413
- VernacularTitle:靶向B7-H3的实体瘤免疫治疗新进展
- Author:
Wu SHUO
1
;
He WEI
;
Hu PENGWU
;
Hui KAIYUAN
;
Jiang YANTING
;
Jiang XIAODONG
Author Information
1. 南京医科大学连云港临床医学院放疗科(江苏省 连云港市 222000)
- Publication Type:Journal Article
- Keywords:
B7-H3;
immunotherapy;
solid tumors;
combination therapy;
review
- From:
Chinese Journal of Clinical Oncology
2024;51(24):1291-1295
- CountryChina
- Language:Chinese
-
Abstract:
B7-H3,a member of the B7 family within the immunoglobulin superfamily,is aberrantly expressed in tumor tissues and can be in-duced by immune cells,but is minimally expressed or not expressed in normal tissues.B7-H3 has gained attention for its ability to induce malignant behaviors in tumors and promote cancer progression through various complex pathways.Immunotherapy targeting B7-H3 has shown significant efficacy in clinical trials by modulating the immune system to enhance anti-tumor immune responses.We comprehens-ively summarize the abnormal expression and impact of B7-H3 in various human tumor types,and its role in immunotherapy,highlighting recent advances in clinical research targeting B7-H3.These findings suggest that B7-H3 holds great value as a future target for cancer dia-gnosis and treatment.
